Janumet · DIN 02333864 · 50 mg & 850 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.Discontinued August 13, 2025 · checked November 19, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Janumet · DIN 02333864
Manufacturer: Merck Canada Inc.; listing date 2012-02-29
Health Canada: Cancelled post market since 2025-08-13 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Merck canada inc · schedule Prescription
Ministry pays: $0.4446 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333864)
Source record
DIN 02333864: Janumet
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id MEK
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.7785; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333864
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81955
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since August 13, 2025 — choose a marketed DIN from the same-category list.